Optimisation of the safety and efficacy of protein kinase inhibitors using endogenous and dietary biomarkers

许多抗癌新药都是“激酶抑制剂”药物的一部分。虽然这些药物在治疗一系列不同的癌症方面是有效的，但通过更明智地决定特定个人应该接受的药物剂量，仍然有机会提高有效性和安全性。这项研究的目的是评估接受治疗的个人血液中正常存在的化学物质水平是否可以用来指导个人应该接受的最佳剂量。

Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.